Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract

American Journal of Surgical Pathology

Volumn 31, Issue 6, 2007, Pages 938-946

  Eiber, Matthias ^a   Van Oers, Johanna M M ^d   Zwarthoff, Ellen C ^d   Van Der Kwast, Theo H ^d   Ulrich, Oehler ^b   Helpap, Burkhard ^b   Stoerkel, Stephan ^c   Blaszyk, Hagen ^e   Cheville, John ^f   Sauter, Guido ^g   Wild, Peter J ^g   Stoehr, Robert ^a   Hofstaedter, Ferdinand ^a   Hartmann, Arndt ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Institute of Pathology   (Germany)

^c HELIOS KLINIKUM WUPPERTAL   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

FGFR3; Inverted papilloma; Inverted urothelial carcinoma; mib 1; Molecular markers

Indexed keywords

CYTOKERATIN 20; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; FGFR3 PROTEIN, HUMAN; MICROSATELLITE DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 17P; CHROMOSOME 9P; CHROMOSOME 9Q; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVERTED PAPILLOMA; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PATHOLOGIST; SCHOOL CHILD; TUMOR RECURRENCE; URINARY TRACT; UROLOGY; CARCINOMA; DIFFERENTIAL DIAGNOSIS; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; OBSERVER VARIATION; PATHOLOGY; POLYMERASE CHAIN REACTION; URINARY TRACT CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; PAPILLOMA, INVERTED; POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 34447301827     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000249448.13466.75     Document Type: Article

References (51)

1. Abel PD, Henderson D, Bennett MK, et al. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol. 1998;62:339-342.
2. Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol. 1997;21:1057-1068.
3. Asano K, Miki J, Maeda S, et al. Clinical studies on inverted papilloma of the urinary tract: report of 48 cases and review of the literature [review]. J Urol. 2003;170:1209-1212.
4. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955-1959.
5. Bol MG, Baak JP, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169:1291-1294.
6. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer [review]. Cancer Res. 1998;58:5248-5257.
7. Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol. 2004;35:1499-1504.
8. Burger M, Burger SJ, Denzinger S, et al. Elevated microsatellite instability at selected tetranucleotide repeats does not correlate with clinicopathologic features of bladder cancer. Eur Urol. 2006; [Epub ahead of print].
9. Cameron KM, Lupton CH. Inverted papilloma of the lower urinary tract. Br J Urol. 1976;48:567-577.
10. Campbell PA, Conrad RJ, Campbell CM, et al. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Internat. 2004;93:1228-1231.
11. Caro DJ, Tessler A. Inverted papilloma of the bladder: a distinct urological lesion [review]. Cancer. 1978;42:708-713.
12. Catto JW, Azzouzi AR, Amira N, et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene. 2003;22:8699-8706.
13. Cheville JC, Wu K, Sebo TJ, et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma? Cancer. 2000;88:632-636.
14. Demokan S, Muslumanoglu M, Yazici H, et al. Investigation of microsatellite instability in Turkish breast cancer patients. Pathol Oncol Res. 2002;8:138-141.
15. Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749-4756.
16. Dietmaier W, Gansbauer S, Beyser K, et al. Microsatellite instability in tumor and nonneoplastic colorectal cells from hereditary nonpolyposis colorectal cancer and sporadic high microsatellite-instable tumor patients. Pathobiology. 2000;68:227-231.
17. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARCC Press; 2004.
18. Goertchen R, Seidenschnur A, Stosiek P. Clinical pathology of inverted papillomas of the urinary bladder. A complex morphologic and catamnestic study. Pathologe. 1994;15:279-285.
19. Grainger R, Gikas PW, Grossman HB. Urothelial carcinoma occurring within an inverted papilloma of the ureter. J Urol. 1990;143:802-804.
20. Gray D, Obermann EC, Evans M, et al. MIB-1 and MCM-2 immunohistochemical analysis does not aid in identification of serrated colorectal polyps with abnormal proliferation. Am J Clin Pathol. 2006;125:407-412.
21. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet. 1999;353:974-977.
22. Hartmann A, Rosner U, Schlake G, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest. 2000;80:709-718.
23. Hartmann A, Hofstaedter F, Molekulare pathogenese des harnblasenkarzinoms und pathologische diagnostik. Der Onkologe. 2002;9:929-939.
24. Hartmann A, Zanardo L, Bocker-Edmonston T, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 2002;62:6796-6802.
25. Hartmann A, Dietmaier W, Hofstadter F, et al. Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability. Hum Pathol. 2003;34:222-227.
26. Henderson DW, Allen PW, Bourne AJ. Inverted urinary papilloma: report of five cases and review of the literature. Virchows Arch A Pathol Anat Histol. 1975;366:177-186.
27. Kessler HH, Muhlbauer G, Stelzl E, et al. Fully automated nucleic acid extraction: MagNA Pure LC. Clin Chem. 2001;47:1124-1126.
28. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 2006;27:361-373.
29. Kunze E, Schauer A, Schmitt M. Histology and histogenesis of two different types of inverted urothelial papillomas. Cancer. 1983;15:348-358.
30. Loeb LA. A mutator phenotype in cancer [review]. Cancer Res. 2001;61:3230-3239.
31. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002;168:968-972.
32. Richter J, Jiang F, Görög JP, et al. Marked genetic differences between pTa and pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57:2860-2864.
33. Risio M, Coverlizza S, Lasaponara F, et al. Inverted urothelial papilloma: a lesion with malignant potential. Eur Urol. 1988;14:333-338.
34. Rueschoff J, Dietmaier W, Luttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815-1825.
35. Simon R. Genetics and predictive factors of non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon: IARCC Press; 2004:120-122.
36. Singer G, Kallinowski T, Hartmann A, et al. Different types of microsatellite instability in ovarian carcinoma. Int J Cancer. 2004;112:643-646.
37. Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications [review]. Histol Histopathol. 1999;14:657-664.
38. Spevack L, Herschorn S, Srigley J. Inverted papilloma of the upper urinary tract [review]. J Urol. 1995;153:1202-1204.
39. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004;84:465-478.
40. Sung MT, Eble JN, Wang M, et al. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol. 2006;21;[Epub ahead of print].
41. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Internat. 2000;85:48-53.
42. van Oers JM, Lurkin I, van Exsel AJ, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005;11:7743-7748.
43. van Oers JM, Adam C, Denzinger S, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer. 2006;119:1212-1215.
44. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;15:1265-1268.
45. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912-1921.
46. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;15:1911-1914.
47. Wild PJ, Reichle A, Andreesen R, et al. Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin Cancer Res. 2004;10:556-564.
48. Witjes JA, van Balken MR, van de Kaa CA. The prognostic value of a primary inverted papilloma of the urinary tract [review]. J Urol. 1997;158:1500-1505.
49. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways [review]. Nat Rev Cancer. 2005;5:713-725.
50. Xu L, Chow J, Bonacum J, et al. Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer. 2001;91:200-204.
51. Zhao J, Richter J, Wagner U, et al. Chromosomal imbalances in non-invasive papillary neoplasms (pTa). Cancer Res. 1999;59:4658-4661.